WO2007123777A3 - Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses - Google Patents
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses Download PDFInfo
- Publication number
- WO2007123777A3 WO2007123777A3 PCT/US2007/008034 US2007008034W WO2007123777A3 WO 2007123777 A3 WO2007123777 A3 WO 2007123777A3 US 2007008034 W US2007008034 W US 2007008034W WO 2007123777 A3 WO2007123777 A3 WO 2007123777A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hif
- compositions
- activation
- methods
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78737306P | 2006-03-30 | 2006-03-30 | |
US60/787,373 | 2006-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007123777A2 WO2007123777A2 (en) | 2007-11-01 |
WO2007123777A3 true WO2007123777A3 (en) | 2008-10-16 |
Family
ID=38625495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/008034 WO2007123777A2 (en) | 2006-03-30 | 2007-03-30 | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
Country Status (2)
Country | Link |
---|---|
US (1) | US8968702B2 (en) |
WO (1) | WO2007123777A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140122283A (en) | 2009-11-06 | 2014-10-17 | 에르피오 세러퓨틱스 인코포레이티드 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
US20140249097A1 (en) * | 2010-09-30 | 2014-09-04 | Mark W. Dewhirst | Inhibition of HIF-1 activation for Anti-Tumor and Anti-Inflammatory responses |
SG11201607795UA (en) | 2014-04-08 | 2016-10-28 | Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2020102252A1 (en) * | 2018-11-12 | 2020-05-22 | Arjomand Nick Cyrus | Cancer screening and therapeutics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215528A1 (en) * | 2000-04-26 | 2003-11-20 | Queens University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US6946484B2 (en) * | 2000-04-26 | 2005-09-20 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114951A (en) * | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5468253A (en) * | 1993-01-21 | 1995-11-21 | Ethicon, Inc. | Elastomeric medical device |
US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5612310A (en) * | 1993-05-24 | 1997-03-18 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
JP3220331B2 (en) * | 1993-07-20 | 2001-10-22 | エチコン・インコーポレーテツド | Absorbable liquid copolymers for parenteral administration |
US5411554A (en) * | 1993-07-20 | 1995-05-02 | Ethicon, Inc. | Liquid polymer filled envelopes for use as surgical implants |
AU706434B2 (en) * | 1994-10-18 | 1999-06-17 | Ethicon Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
US5599852A (en) * | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
US5688900A (en) * | 1995-01-19 | 1997-11-18 | Ethicon, Inc. | Absorbable polyalkylene diglycolates |
US5677350A (en) * | 1995-06-07 | 1997-10-14 | Wisconsin Alumni Research Foundation | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes |
US6022737A (en) * | 1995-11-02 | 2000-02-08 | Amgen Inc. | Formulations for non-viral in vivo transfection in the lungs |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6083693A (en) | 1996-06-14 | 2000-07-04 | Curagen Corporation | Identification and comparison of protein-protein interactions that occur in populations |
US7009034B2 (en) * | 1996-09-23 | 2006-03-07 | Incept, Llc | Biocompatible crosslinked polymers |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US6423818B1 (en) * | 1999-07-30 | 2002-07-23 | Takehisa Matsuda | Coumarin endcapped absorbable polymers |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US7011842B1 (en) * | 2002-06-21 | 2006-03-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US20110054023A1 (en) * | 2006-03-30 | 2011-03-03 | Duke University | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses |
-
2007
- 2007-03-30 US US11/731,719 patent/US8968702B2/en active Active
- 2007-03-30 WO PCT/US2007/008034 patent/WO2007123777A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215528A1 (en) * | 2000-04-26 | 2003-11-20 | Queens University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US6946484B2 (en) * | 2000-04-26 | 2005-09-20 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
Also Published As
Publication number | Publication date |
---|---|
US8968702B2 (en) | 2015-03-03 |
WO2007123777A2 (en) | 2007-11-01 |
US20070297984A1 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kiran et al. | Sirtuin 7 in cell proliferation, stress and disease: Rise of the Seventh Sirtuin! | |
WO2010003022A8 (en) | Isoindolone derivatives as mek kinase inhibitors and methods of use | |
EP3103476A3 (en) | Antibodies against a proliferating inducing ligand (april) | |
MX2009001309A (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes. | |
MY158106A (en) | Inhibitors of e1 activating enzymes | |
WO2007065010A3 (en) | Anti-angiogenesis compounds | |
WO2007123892A3 (en) | Raf inhibitors and their uses | |
MX2008001903A (en) | Protein kinase modulation by hops and acacia products. | |
WO2010141738A3 (en) | Compositions and method for inhibiting tumor growth | |
EP3050566A3 (en) | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors | |
WO2008128072A3 (en) | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders | |
NZ594746A (en) | Inhibitors of iap | |
EP4282428A3 (en) | Anti-cldn6 antibody | |
WO2008131354A3 (en) | Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment | |
WO2007053648A3 (en) | Compositions and methods for treating and diagnosing cancer | |
WO2007067812A3 (en) | Protein kinase modulation by hops and acacia products | |
WO2012092471A3 (en) | Novel tubulin inhibitors and methods of using the same | |
IN2012DN01964A (en) | ||
WO2009070244A3 (en) | Methods for inhibiting fascin | |
WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
WO2011047770A3 (en) | Pyrazolopyrimidine derivatives | |
WO2007123777A3 (en) | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses | |
WO2011066263A8 (en) | Transcription factor inhibitors and related compositions, formulations and methods | |
WO2006003068A3 (en) | Alpha-amino acid derivatives with antiinflammatory activity | |
WO2006031977A3 (en) | Inhibition of pancreatic cancer cell growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07754544 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07754544 Country of ref document: EP Kind code of ref document: A2 |